Linezolid-associated peripheral neuropathy |
| |
Authors: | Rho Jennifer P Sia Irene G Crum Brian A Dekutoski Mark B Trousdale Robert T |
| |
Affiliation: | Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA. |
| |
Abstract: | Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|